The efficacy of vericiguat on improving quality of life among patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis

Abstract

\n \n \n Heart Failure with Preserved Ejection Fraction remains to be a global health concern since there is no proven effective therapy as of the moment. Data from 2017 have shown that half of the population with heart failure has preserved ejection fraction (HFpEF) and there is an observed increasing trend in numbers. HFpEF carries significant disease burden and greatly affects Quality of Life.\n \n \n \n To determine the efficacy of Vericiguat in improving the quality of life among patients with Heart Failure with preserved Ejection Fraction.\n \n \n \n A comprehensive literature search was made by the authors for Randomized Controlled Trials comparing the efficacy of Vericiguat with placebo in improving the Quality of Life among patients with HFpEF. Authors were contacted if there were missing data. Two authors independently extracted data and appraised the different studies characteristics, quality and outcomes. RevMan 5.4 was used for the statistical analysis.\n \n \n \n The authors found two RCTs with 1,218 participants. Pooled analysis of the moderate to high quality studies showed no statistically significant mean difference in the different domains of the Kansas City Cardiomyopathy Questionnaire including the Clinical Summary Score, Physical Limitation Score, Total Symptom Score, and Overall Summary Score (1.61 [−1.44, 4.66] p=0.30; 2.22 [−1.16, 5.60] p=0.20; 0.14 [−3.00, 3.29] p=0.93; and 1.35 [−1.65, 4.35] p=0.38, respectively) between Vericiguat and placebo. For the safety and adverse events, there was no statistically significant difference between Vericiguat and placebo with regards to syncope, hypotension and death, with RR of 1.10 [0.06, 18.61] p=0.95; 1.22 [0.70, 2.14] p=0.48 and 1.79 [0.67, 4.75] p=0.24, respectively.\n \n \n \n Vericiguat compared to placebo did not significantly improve the Quality of Life among adult patients with Heart Failure with Preserved Ejection Fraction.\n \n \n \n Type of funding sources: None.\n